{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:36:05Z","timestamp":1793075765051,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The financial burden of tuberculosis (TB) can hinder patients and their families, creating obstacles throughout the care cascade, despite TB prevention and control being provided free of charge. In Myanmar, patients can visit private providers operating under public-private mix (PPM) schemes, where TB services (diagnosis and treatment) are typically offered at no cost. The study focused on quantifying the financial burden faced by TB patients seeking care from Myanmar's PPM providers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional telephone survey included 695 adults seeking TB treatment [drug-susceptible TB (DS-TB) and retreatment TB] from various private providers in four states and regions with high TB burden in Myanmar. Telephone interviews were conducted in May and June 2022. Both direct and indirect costs incurred from the patient and their household perspective were valued in 2022 and estimated throughout pre- and post-TB treatment episodes. The TB-affected households were defined as experiencing catastrophic health expenditure if their expenditure due to TB exceeded 20% of their capacity to pay, as recommended by the World Health Organization. All cost data were collected in Myanmar Kyats (MMK) and converted to USD (1 USD\u2009=\u20091850 MMK as of July 20, 2022). Logistic regression analysis was done to identify the determinants of catastrophic health expenditure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The findings showed patients made a median of 7 times for clinic visits throughout their treatment, with the median total cost for the entire TB treatment being 53.4 US dollars (USD), including direct medical and testing costs (11.9 USD) and direct non-medical patient expenditure (11.6 USD). Pre-treatment costs were higher compared to post-treatment costs (the intensive phase and continuation phase). During the intensive phase, TB care cost was nearly free, but during the continuation phase, it was a median of 2.6 USD. About 34.5% of patients experienced catastrophic health expenditure due to TB treatment, with expenses exceeding 20% of their capacity to pay. Multivariate regression analysis revealed that patients with a history of hospitalization (a\n                      <jats:italic>OR<\/jats:italic>\n                      \u2009=\u200914.84;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), seeking care from regions other than Yangon (a\n                      <jats:italic>OR<\/jats:italic>\n                      \u2009=\u20092.6;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), and using coping strategies (a\n                      <jats:italic>OR<\/jats:italic>\n                      \u2009=\u200912.53;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), were more likely to face catastrophic financial burdens. Higher monthly household income (over 162 USD) was associated with a decreased risk of incurring catastrophic health expenditure (a\n                      <jats:italic>OR<\/jats:italic>\n                      \u2009=\u20090.38;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TB patients and their households in Myanmar faced risk of catastrophic costs, even when treated in the private sector with free diagnostic charges and anti-TB medicine. The study highlighted the need for additional strategies or policies to make TB care affordable and mitigate the financial burden of TB-affected households.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s40249-024-01248-7","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T23:34:33Z","timestamp":1730763273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Out-of-pocket payment and catastrophic health expenditure of tuberculosis patients in accessing care at public-private mix clinics in Myanmar, 2022"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-6788","authenticated-orcid":false,"given":"Myat Noe Thiri","family":"Khaing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandi","family":"U","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luu","family":"Maw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Htet","family":"Arkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saw Pa Pa","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Me","family":"Thet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"1248_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2019. Geneva."},{"key":"1248_CR2","unstructured":"World Health Organization. WHO global lists of high burden countries for tuberculosis (TB), TB\/HIV and multidrug\/rifampicin-resistant TB (MDR\/RR-TB), 2021\u20132025. 2021. https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-tuberculosis\/who_globalhbcliststb_2021-2025_backgrounddocument.pdf?sfvrsn=f6b854c2_9. Accessed 1 July 2023."},{"key":"1248_CR3","unstructured":"World Health Organization. Global Tuberculosis Report 2022. 2022. http:\/\/apps.who.int\/bookorders. Accessed 1 July 2023."},{"key":"1248_CR4","unstructured":"World Health Organization. Addressing poverty in TB control: options for national TB control programmes. 2005."},{"issue":"12","key":"1248_CR5","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.socscimed.2009.03.041","volume":"68","author":"K L\u00f6nnroth","year":"2009","unstructured":"L\u00f6nnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 2009;68(12):2240\u20136. https:\/\/doi.org\/10.1016\/j.socscimed.2009.03.041.","journal-title":"Soc Sci Med"},{"issue":"1","key":"1248_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41598-021-04345-x","volume":"12","author":"RM Ghazy","year":"2022","unstructured":"Ghazy RM, El Saeh HM, Abdulaziz S, Hammouda EA, Elzorkany AM, Khidr H, et al. A systematic review and meta-analysis of the catastrophic costs incurred by tuberculosis patients. Sci Rep. 2022;12(1):558. https:\/\/doi.org\/10.1038\/s41598-021-04345-x.","journal-title":"Sci Rep"},{"key":"1248_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12889-015-2338-5","volume":"15","author":"TT Hoang","year":"2015","unstructured":"Hoang TT, Nguyen NV, Dinh SN, Nguyen HB, Cobelens F, Thwaites G, et al. Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam. BMC Public Health. 2015;15:980. https:\/\/doi.org\/10.1186\/s12889-015-2338-5.","journal-title":"BMC Public Health"},{"key":"1248_CR8","unstructured":"World Health Organization. Framework for the engagement of all health care providers in the management of drug-resistant tuberculosis. 2015. WHO reference number: WHO\/HTM\/TB\/2015.04. www.who.int. Accessed 7 July 2023."},{"issue":"5","key":"1248_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/tropicalmed8050265","volume":"8","author":"RP Suseela","year":"2023","unstructured":"Suseela RP, Shannawaz M. Engaging the private health service delivery sector for TB care in India\u2014miles to go! Trop Med Infect Dis. 2023;8(5):265. https:\/\/doi.org\/10.3390\/tropicalmed8050265.","journal-title":"Trop Med Infect Dis"},{"key":"1248_CR10","unstructured":"World Health Organization. Global tuberculosis report 2016."},{"key":"1248_CR11","unstructured":"World Health Organization. 2023. https:\/\/www.who.int\/southeastasia\/news\/feature-stories\/detail\/how-myanmar-achieved-the-2020-milestone-of-reducing-TB-disease-burden. Accessed 1 July 2023."},{"key":"1248_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41182-019-0154-9","volume":"47","author":"KK Htwe","year":"2019","unstructured":"Htwe KK, Kyaw NTT, Kumar AMV, Kyaw KWY, Oo MM, Thwin T, et al. Pre-treatment loss to follow-up and treatment delay among bacteriologically confirmed tuberculosis patients diagnosed in Mandalay Region, Myanmar. Trop Med Health. 2019;47:30. https:\/\/doi.org\/10.1186\/s41182-019-0154-9.","journal-title":"Trop Med Health"},{"issue":"3","key":"1248_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/tropicalmed6030130","volume":"6","author":"ST Aung","year":"2021","unstructured":"Aung ST, Thu A, Aung HL, Thu M. Measuring catastrophic costs due to tuberculosis in Myanmar. Trop Med Infect Dis. 2021;6(3):130. https:\/\/doi.org\/10.3390\/tropicalmed6030130.","journal-title":"Trop Med Infect Dis"},{"issue":"6","key":"1248_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000588","volume":"2","author":"ST Aung","year":"2022","unstructured":"Aung ST, Nyunt WW, Moe MM, Aung HL, Lwin T. The fourth national tuberculosis prevalence survey in Myanmar. PLoS Glob Public Health. 2022;2(6): e0000588. https:\/\/doi.org\/10.1371\/journal.pgph.0000588.","journal-title":"PLoS Glob Public Health"},{"key":"1248_CR15","volume-title":"The tool to estimate patient\u2019s costs","author":"TB-TCA","year":"2009","unstructured":"TB-TCA. The tool to estimate patient\u2019s costs. The Hague: KNCV; 2009."},{"key":"1248_CR16","first-page":"25","volume":"3","author":"TS Nanjundeswaraswamy","year":"2021","unstructured":"Nanjundeswaraswamy TS, Divakar S. Determination of sample size and sampling methods in applied research. Proc Eng Sci. 2021;3:25\u201332.","journal-title":"Proc Eng Sci"},{"key":"1248_CR17","unstructured":"National Tuberculosis Programme Myanmar. Annual tuberculosis report 2018."},{"key":"1248_CR18","unstructured":"Metrics for Management. Metrics for Management. Equity tool. 2014. https:\/\/www.equitytool.org\/myanmar\/. Accessed 22 Jan 2024."},{"issue":"3","key":"1248_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5588\/pha.20.0017","volume":"10","author":"P Sinha","year":"2020","unstructured":"Sinha P, Carwile M, Bhargava A, Cintron C, Acuna-Villaorduna C, Lakshminarayan S, et al. How much do Indians pay for tuberculosis treatment? A cost analysis. Public Health Action. 2020;10(3):110\u20137. https:\/\/doi.org\/10.5588\/pha.20.0017.","journal-title":"Public Health Action"},{"key":"1248_CR20","unstructured":"Xu K. World Health Organization Distribution of Health Payments and Catastrophic Expenditures Methodology. 2005. https:\/\/www.who.int\/publications\/i\/item\/EIP-FER-DP.05.2. Accessed 23 Oct 2023."},{"key":"1248_CR21","unstructured":"World Health Organization. Tuberculosis patient cost surveys: a handbook. 2017. http:\/\/apps.who.int\/bookorders. Accessed 28 June 2023."},{"key":"1248_CR22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1037\/h0070888","volume":"24","author":"H Hotelling","year":"1933","unstructured":"Hotelling H. Analysis of a complex of statistical variables into principal components. J Educ Psychol. 1933;24:498\u2013520.","journal-title":"J Educ Psychol"},{"issue":"1","key":"1248_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.9745\/GHSP-D-15-00384","volume":"4","author":"NM Chakraborty","year":"2016","unstructured":"Chakraborty NM, Fry K, Behl R, Longfield K. Simplified asset indices to measure wealth and equity in health programs: a reliability and validity analysis using survey data from 16 countries. Glob Health Sci Pract. 2016;4(1):141\u201354. https:\/\/doi.org\/10.9745\/GHSP-D-15-00384.","journal-title":"Glob Health Sci Pract"},{"issue":"9","key":"1248_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2471\/BLT.18.209031","volume":"96","author":"J Cylus","year":"2018","unstructured":"Cylus J, Thomson S, Evetovits T. Catastrophic health spending in Europe: equity and policy implications of different calculation methods. Bull World Health Organ. 2018;96(9):599\u2013609. https:\/\/doi.org\/10.2471\/BLT.18.209031.","journal-title":"Bull World Health Organ"},{"key":"1248_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40249-016-0100-6","volume":"5","author":"C Zhou","year":"2016","unstructured":"Zhou C, Long Q, Chen J, Xiang L, Li Q, Tang S, et al. Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China. Infect Dis Poverty. 2016;5:6. https:\/\/doi.org\/10.1186\/s40249-016-0100-6.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"1248_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2049-9957-2-21","volume":"2","author":"KN Ukwaja","year":"2013","unstructured":"Ukwaja KN, Alobu I, Abimbola S, Hopewell PC. Household catastrophic payments for tuberculosis care in Nigeria: incidence, determinants, and policy implications for universal health coverage. Infect Dis Poverty. 2013;2(1):21. https:\/\/doi.org\/10.1186\/2049-9957-2-21.","journal-title":"Infect Dis Poverty"},{"issue":"10","key":"1248_CR27","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/tmi.12365","volume":"19","author":"S Laokri","year":"2014","unstructured":"Laokri S, Dramaix-Wilmet M, Kassa F, Anagonou S, Dujardin B. Assessing the economic burden of illness for tuberculosis patients in Benin: determinants and consequences of catastrophic health expenditures and inequities. Trop Med Int Health. 2014;19(10):1249\u201358. https:\/\/doi.org\/10.1111\/tmi.12365.","journal-title":"Trop Med Int Health"},{"issue":"10","key":"1248_CR28","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1016\/S2214-109X(23)00369-8","volume":"11","author":"A Portnoy","year":"2023","unstructured":"Portnoy A, Yamanaka T, Nguhiu P, Nishikiori N, Garcia Baena I, Floyd K, et al. Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis. Lancet Glob Health. 2023;11(10):e1640\u20137. https:\/\/doi.org\/10.1016\/S2214-109X(23)00369-8.","journal-title":"Lancet Glob Health"},{"key":"1248_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s13104-015-1560-7","volume":"8","author":"Y Mahendradhata","year":"2015","unstructured":"Mahendradhata Y, Lestari T, Probandari A, Indriarini LE, Burhan E, Mustikawati D, et al. How do private general practitioners manage tuberculosis cases? A survey in eight cities in Indonesia. BMC Res Notes. 2015;8:564. https:\/\/doi.org\/10.1186\/s13104-015-1560-7.","journal-title":"BMC Res Notes"},{"key":"1248_CR30","first-page":"188","volume":"52","author":"M Muniyandi","year":"2005","unstructured":"Muniyandi M, Ramachandran R, Balasubramanian R. Costs to patients with tuberculosis treated under DOTS. Indian J Tuberc. 2005;52:188\u201396.","journal-title":"Indian J Tuberc"},{"issue":"3","key":"1248_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5588\/ijtld.12.0368","volume":"17","author":"V Mauch","year":"2013","unstructured":"Mauch V, Bonsu F, Gyapong M, Awini E, Suarez P, Marcelino B, et al. Free tuberculosis diagnosis and treatment are not enough: patient cost evidence from three continents. Int J Tuberc Lung Dis. 2013;17(3):381\u20137. https:\/\/doi.org\/10.5588\/ijtld.12.0368.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"1248_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-3156.2009.02427","volume":"15","author":"Q Liu","year":"2010","unstructured":"Liu Q, Smith H, Wang Y, Tang S, Wang Q, Garner P. Tuberculosis patient expenditure on drugs and tests in subsidised, public services in China: a descriptive study. Trop Med Int Health. 2010;15(1):26\u201332. https:\/\/doi.org\/10.1111\/j.1365-3156.2009.02427.","journal-title":"Trop Med Int Health"},{"issue":"9","key":"1248_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162796","volume":"11","author":"F Morishita","year":"2016","unstructured":"Morishita F, Yadav RP, Eang MT, Saint S, Nishikiori N. Mitigating financial burden of tuberculosis through active case finding targeting household and neighborhood contacts in Cambodia. PLoS ONE. 2016;11(9): e0162796. https:\/\/doi.org\/10.1371\/journal.pone.0162796.","journal-title":"PLoS ONE"},{"issue":"6","key":"1248_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-036892","volume":"10","author":"LF Assebe","year":"2020","unstructured":"Assebe LF, Negussie EK, Jbaily A, Tolla MTT, Johansson KA. Financial burden of HIV and TB among patients in Ethiopia: a cross-sectional survey. BMJ Open. 2020;10(6): e036892. https:\/\/doi.org\/10.1136\/bmjopen-2020-036892.","journal-title":"BMJ Open"},{"issue":"1","key":"1248_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40249-017-0382-3","volume":"7","author":"A Fuady","year":"2018","unstructured":"Fuady A, Houweling TAJ, Mansyur M, Richardus JH. Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia\u2019s implementation of universal health coverage. Infect Dis Poverty. 2018;7(1):3. https:\/\/doi.org\/10.1186\/s40249-017-0382-3.","journal-title":"Infect Dis Poverty"},{"issue":"6","key":"1248_CR36","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1183\/09031936.00193413","volume":"43","author":"T Tanimura","year":"2014","unstructured":"Tanimura T, Jaramillo E, Weil D, Raviglione M, L\u00f6nnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014;43(6):1763\u201375. https:\/\/doi.org\/10.1183\/09031936.00193413.","journal-title":"Eur Respir J"},{"key":"1248_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/1471-2458-11-393","volume":"11","author":"Q Long","year":"2011","unstructured":"Long Q, Smith H, Zhang T, Tang S, Garner P. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health. 2011;11:393. https:\/\/doi.org\/10.1186\/1471-2458-11-393.","journal-title":"BMC Public Health"},{"key":"1248_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/1745-6215-15-236","volume":"15","author":"E Lutge","year":"2014","unstructured":"Lutge E, Lewin S, Volmink J. Economic support to improve tuberculosis treatment outcomes in South Africa: a qualitative process evaluation of a cluster randomized controlled trial. Trials. 2014;15:236. https:\/\/doi.org\/10.1186\/1745-6215-15-236.","journal-title":"Trials"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-024-01248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-024-01248-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-024-01248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:05:49Z","timestamp":1730804749000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-024-01248-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1186\/s40249-024-01248-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4591754\/v1","asserted-by":"object"}]},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by Population Services International Research Ethics Board (PSI REB). All participants included in the analysis had provided informed oral consent. Data were anonymized prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}